System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework
AMR-X Collaborators,Kathryn Abel,Emily Agnew,James Amos,Natalie Armstrong,Darius Armstrong-James,Thomas Ashfield,Stephen Aston,J Kenneth Baillie,Steven Baldwin,Gavin Barlow,Victoria Bartle,Julia Bielicki,Colin Brown,Enitan Carrol,Michelle Clements,Graham Cooke,Aaron Dane,Paul Dark,Jeremy Day,Anthony de-Soyza,Andrew Dowsey,Stephanie Evans,David Eyre,Timothy Felton,Tom Fowler,Robbie Foy,Karen Gannon,Alessandro Gerada,Anna Goodman,Tracy Harman,Gail Hayward,Alison Holmes,Susan Hopkins,Philip Howard,Alexander Howard,Yingfen Hsia,Gwen Knight,Nick Lemoine,James Koh,Alasdair Macgowan,Charis Marwick,Catrin Moore,Seamus O'Brien,Raymond Oppong,Sharon Peacock,Sarah Pett,Koen Pouwels,Chris Queree,Najib Rahman,Mark Sculpher,Laura Shallcross,Michael Sharland,Jasvinder Singh,Karen Stoddart,Emma Thomas-Jones,Andrew Townsend,Andrew Ustianowski,Tjeerd Van Staa,Sarah Walker,Peter White,Paul Wilson,Iain Buchan,Beth Woods,Peter Bower,Martin Llewelyn,William Hope
DOI: https://doi.org/10.1016/S2666-5247(24)00003-X
Abstract:Antimicrobial resistance (AMR) threatens human, animal, and environmental health. Acknowledging the urgency of addressing AMR, an opportunity exists to extend AMR action-focused research beyond the confines of an isolated biomedical paradigm. An AMR learning system, AMR-X, envisions a national network of health systems creating and applying optimal use of antimicrobials on the basis of their data collected from the delivery of routine clinical care. AMR-X integrates traditional AMR discovery, experimental research, and applied research with continuous analysis of pathogens, antimicrobial uses, and clinical outcomes that are routinely disseminated to practitioners, policy makers, patients, and the public to drive changes in practice and outcomes. AMR-X uses connected data-to-action systems to underpin an evaluation framework embedded in routine care, continuously driving implementation of improvements in patient and population health, targeting investment, and incentivising innovation. All stakeholders co-create AMR-X, protecting the public from AMR by adapting to continuously evolving AMR threats and generating the information needed for precision patient and population care.